Skip to main content
Top
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer

Authors: Yulong Wang, Haiyan Dong, Hongyan Wu, Li Zhang, Kai Yuan, Hongqiang Chen, Mingwen Jiao, Rongzhan Fu

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

The false negative rate of sentinel lymph node biopsy (SLNB) is 5-10%, and results in improper patient management. The study was to assess the value of ultrasound-suspicious axillary lymph node biopsy (USALNB) in patients with early breast cancer, and to compare SLNB combined with USALNB (SLNB + USALNB) with SLNB alone.

Methods

From January 2010 to July 2013, 216 patients with early breast cancer were enrolled consecutively at the Department of Breast and Thyroid Surgery, Qianfoshan Hospital, Shandong University. All patients underwent wire localization of the suspicious node by color Doppler ultrasonography, followed by SLNB 2–3 hours later, suspicious node lymphadenectomy, and level ≥ II axillary dissection (as the gold standard). The predictive values of node status between SLNB + USALNB and SLNB alone were compared.

Results

The success rate of SLNB was 99.1% (214/216). After axillary dissection, 71 patients were confirmed with axillary lymph node metastases by pathological examinations. Eight false negatives were observed using SLNB alone, resulting in sensitivity of 88.7%, specificity of 100%, false negative rate of 11.3%, and false positive rate of 0% in predicting the axillary node status. SLNB + USALNB resulted in sensitivity of 97.2%, specificity of 100%, false negative rate of 2.8%, and false positive rate of 0%. The false negative rate of SLNB + USALNB was significantly different from that of SLNB alone (P = 0.031).

Conclusions

SLNB + USALNB seems to be a low-risk procedure that might be useful in reducing the false negative rate of SLNB, improving the accuracy of axillary nodes evaluation in early breast cancer.
Literature
1.
go back to reference Brenin D, Morrow M. Conventional axillary dissection: extent, local control, and morbidity. Seninars in breast diseases. 1998;1:118–24. Brenin D, Morrow M. Conventional axillary dissection: extent, local control, and morbidity. Seninars in breast diseases. 1998;1:118–24.
2.
go back to reference Goyal A, Newcombe RG, Chhabra A, Mansel RE, Group AT. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer–results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203–8.CrossRefPubMed Goyal A, Newcombe RG, Chhabra A, Mansel RE, Group AT. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer–results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203–8.CrossRefPubMed
3.
go back to reference White Jr RL, Wilke LG. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg. 2004;70:420–4.PubMed White Jr RL, Wilke LG. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg. 2004;70:420–4.PubMed
4.
go back to reference Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T. National Surgical Adjuvant B, Bowel P. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.CrossRefPubMed Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T. National Surgical Adjuvant B, Bowel P. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.CrossRefPubMed
5.
go back to reference Cools-Lartigue J, Meterissian S. Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review. World J Surg. 2012;36:46–54.CrossRefPubMed Cools-Lartigue J, Meterissian S. Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review. World J Surg. 2012;36:46–54.CrossRefPubMed
6.
go back to reference Ganott MA, Zuley ML, Abrams GS, Lu AH, Kelly AE, Sumkin JH, et al. Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer. ISRN Oncol. 2014;2014:703160.PubMedPubMedCentral Ganott MA, Zuley ML, Abrams GS, Lu AH, Kelly AE, Sumkin JH, et al. Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer. ISRN Oncol. 2014;2014:703160.PubMedPubMedCentral
7.
go back to reference Solon JG, Power C, Al-Azawi D, Duke D, Hill AD. Ultrasound-guided core biopsy: an effective method of detecting axillary nodal metastases. J Am Coll Surg. 2012;214:12–7.CrossRefPubMed Solon JG, Power C, Al-Azawi D, Duke D, Hill AD. Ultrasound-guided core biopsy: an effective method of detecting axillary nodal metastases. J Am Coll Surg. 2012;214:12–7.CrossRefPubMed
8.
go back to reference Luparia A, Campanino P, Cotti R, Lucarelli D, Durando M, Mariscotti G, et al. Role of axillary ultrasound in the preoperative diagnosis of lymph node metastases in patients affected by breast carcinoma. Radiol Med. 2010;115:225–37.CrossRefPubMed Luparia A, Campanino P, Cotti R, Lucarelli D, Durando M, Mariscotti G, et al. Role of axillary ultrasound in the preoperative diagnosis of lymph node metastases in patients affected by breast carcinoma. Radiol Med. 2010;115:225–37.CrossRefPubMed
9.
go back to reference Mills P, Sever A, Weeks J, Fish D, Jones S, Jones P. Axillary ultrasound assessment in primary breast cancer: an audit of 653 cases. Breast J. 2010;16:460–3.CrossRefPubMed Mills P, Sever A, Weeks J, Fish D, Jones S, Jones P. Axillary ultrasound assessment in primary breast cancer: an audit of 653 cases. Breast J. 2010;16:460–3.CrossRefPubMed
10.
go back to reference Cody 3rd HS. Current surgical management of breast cancer. Curr Opin Obstet Gynecol. 2002;14:45–52.CrossRefPubMed Cody 3rd HS. Current surgical management of breast cancer. Curr Opin Obstet Gynecol. 2002;14:45–52.CrossRefPubMed
12.
go back to reference Cancer Staging Manual AJC. 6th edition. Chicago: American Joint Committee on Cancer; 2002. Cancer Staging Manual AJC. 6th edition. Chicago: American Joint Committee on Cancer; 2002.
13.
go back to reference Esen G, Gurses B, Yilmaz MH, Ilvan S, Ulus S, Celik V, et al. Gray scale and power Doppler US in the preoperative evaluation of axillary metastases in breast cancer patients with no palpable lymph nodes. Eur Radiol. 2005;15:1215–23.CrossRefPubMed Esen G, Gurses B, Yilmaz MH, Ilvan S, Ulus S, Celik V, et al. Gray scale and power Doppler US in the preoperative evaluation of axillary metastases in breast cancer patients with no palpable lymph nodes. Eur Radiol. 2005;15:1215–23.CrossRefPubMed
14.
go back to reference Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609.CrossRefPubMed Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609.CrossRefPubMed
15.
go back to reference Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentral Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentral
16.
go back to reference Yamashita M, Hovanessian-Larsen L, Sener SF. The role of axillary ultrasound in the detection of metastases from primary breast cancers. Am J Surg. 2013;205:242–4. discussion 244–245.CrossRefPubMed Yamashita M, Hovanessian-Larsen L, Sener SF. The role of axillary ultrasound in the detection of metastases from primary breast cancers. Am J Surg. 2013;205:242–4. discussion 244–245.CrossRefPubMed
17.
go back to reference Sauer T, Suciu V. The role of preoperative axillary lymph node fine needle aspiration in locoregional staging of breast cancer. Ann Pathol. 2012;32:e24–8.CrossRefPubMed Sauer T, Suciu V. The role of preoperative axillary lymph node fine needle aspiration in locoregional staging of breast cancer. Ann Pathol. 2012;32:e24–8.CrossRefPubMed
18.
go back to reference Cserni G. Estimating the overlap between sentinel lymph nodes and axillary node samples in breast cancer. Pathol Oncol Res. 1999;5:129–33.CrossRefPubMed Cserni G. Estimating the overlap between sentinel lymph nodes and axillary node samples in breast cancer. Pathol Oncol Res. 1999;5:129–33.CrossRefPubMed
19.
go back to reference Macmillan RD, Barbera D, Hadjiminas DJ, Rampaul RS, Lee AH, Pinder SE, et al. Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer. 2001;37:1076–80.CrossRefPubMed Macmillan RD, Barbera D, Hadjiminas DJ, Rampaul RS, Lee AH, Pinder SE, et al. Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer. 2001;37:1076–80.CrossRefPubMed
20.
go back to reference Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg. 1998;186:275–83.CrossRefPubMed Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg. 1998;186:275–83.CrossRefPubMed
22.
go back to reference Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol. 2008;15:863–71.CrossRefPubMed Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol. 2008;15:863–71.CrossRefPubMed
23.
go back to reference Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 2006;244:799–804.CrossRefPubMedPubMedCentral Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 2006;244:799–804.CrossRefPubMedPubMedCentral
24.
go back to reference McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.PubMed McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.PubMed
25.
go back to reference Ahlgren J, Holmberg L, Bergh J, Liljegren G. Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol. 2002;28:97–102.CrossRefPubMed Ahlgren J, Holmberg L, Bergh J, Liljegren G. Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol. 2002;28:97–102.CrossRefPubMed
26.
go back to reference Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yang QF, et al. MR-axillography oriented surgical sampling for assessment of nodal status in the selection of patients with breast cancer for axillary lymph nodes dissection. Breast Cancer. 2002;9:69–74.CrossRefPubMed Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yang QF, et al. MR-axillography oriented surgical sampling for assessment of nodal status in the selection of patients with breast cancer for axillary lymph nodes dissection. Breast Cancer. 2002;9:69–74.CrossRefPubMed
27.
go back to reference Hoar FJ, Stonelake PS. A prospective study of the value of axillary node sampling in addition to sentinel lymph node biopsy in patients with breast cancer. Eur J Surg Oncol. 2003;29:526–31.CrossRefPubMed Hoar FJ, Stonelake PS. A prospective study of the value of axillary node sampling in addition to sentinel lymph node biopsy in patients with breast cancer. Eur J Surg Oncol. 2003;29:526–31.CrossRefPubMed
28.
go back to reference Gui GP, Joubert DJ, Reichert R, Ward A, Lakhani S, Osin P, et al. Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer. Eur J Surg Oncol. 2005;31:707–14.CrossRefPubMed Gui GP, Joubert DJ, Reichert R, Ward A, Lakhani S, Osin P, et al. Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer. Eur J Surg Oncol. 2005;31:707–14.CrossRefPubMed
29.
go back to reference Lumachi F, Norberto L, Zanella S, Marino F, Basso SM, Basso U, et al. Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. Anticancer Res. 2011;31:693–7.PubMed Lumachi F, Norberto L, Zanella S, Marino F, Basso SM, Basso U, et al. Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. Anticancer Res. 2011;31:693–7.PubMed
30.
go back to reference Narui K, Ishikawa T, Kito A, Shimizu D, Chishima T, Momiyama N, et al. Observational study of blue dye-assisted four-node sampling for axillary staging in early breast cancer. Eur J Surg Oncol. 2010;36:731–6.CrossRefPubMed Narui K, Ishikawa T, Kito A, Shimizu D, Chishima T, Momiyama N, et al. Observational study of blue dye-assisted four-node sampling for axillary staging in early breast cancer. Eur J Surg Oncol. 2010;36:731–6.CrossRefPubMed
31.
go back to reference Mathelin C, Croce S, Brasse D, Gairard B, Gharbi M, Andriamisandratsoa N, et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res. 2009;29:4119–25.PubMed Mathelin C, Croce S, Brasse D, Gairard B, Gharbi M, Andriamisandratsoa N, et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res. 2009;29:4119–25.PubMed
32.
go back to reference Varghese P, Abdel-Rahman AT, Akberali S, Mostafa A, Gattuso JM, Carpenter R. Methylene blue dye–a safe and effective alternative for sentinel lymph node localization. Breast J. 2008;14:61–7.CrossRefPubMed Varghese P, Abdel-Rahman AT, Akberali S, Mostafa A, Gattuso JM, Carpenter R. Methylene blue dye–a safe and effective alternative for sentinel lymph node localization. Breast J. 2008;14:61–7.CrossRefPubMed
33.
go back to reference Eldrageely K, Vargas MP, Khalkhali I, Venegas R, Burla M, Gonzalez KD, et al. Sentinel lymph node mapping of breast cancer: a case–control study of methylene blue tracer compared to isosulfan blue. Am Surg. 2004;70:872–5.PubMed Eldrageely K, Vargas MP, Khalkhali I, Venegas R, Burla M, Gonzalez KD, et al. Sentinel lymph node mapping of breast cancer: a case–control study of methylene blue tracer compared to isosulfan blue. Am Surg. 2004;70:872–5.PubMed
Metadata
Title
Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer
Authors
Yulong Wang
Haiyan Dong
Hongyan Wu
Li Zhang
Kai Yuan
Hongqiang Chen
Mingwen Jiao
Rongzhan Fu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1331-9

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine